Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry (2022)
https://pubmed.ncbi.nlm.nih.gov/34758105/

Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication (2021)
https://pubmed.ncbi.nlm.nih.gov/34958453/

Identifying Patients With Axial Spondyloarthritis in Large Datasets: Expanding Possibilities for Observational Research (2021)
https://pubmed.ncbi.nlm.nih.gov/33259327/

Clinical Manifestations and Diagnosis of Axial Spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/33105312/

Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34724089/

A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health (2021)
https://pubmed.ncbi.nlm.nih.gov/33313838/

https://pubmed.ncbi.nlm.nih.gov/33313838/ (2021)
https://pubmed.ncbi.nlm.nih.gov/34287723/

The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33655380/

Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study (2021)
https://pubmed.ncbi.nlm.nih.gov/33759081/

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry (2021)
https://pubmed.ncbi.nlm.nih.gov/34822121/

Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods (2020)
https://pubmed.ncbi.nlm.nih.gov/30877217/

Recognizing Axial Spondyloarthritis: A Guide for Primary Care (2020)
https://pubmed.ncbi.nlm.nih.gov/32736944/

Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies (2020)
https://pubmed.ncbi.nlm.nih.gov/32271088/

https://pubmed.ncbi.nlm.nih.gov/32271088/ (2020)
https://pubmed.ncbi.nlm.nih.gov/31575704/

Application of machine learning in the diagnosis of axial spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31033569/

Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016 (2019)
https://pubmed.ncbi.nlm.nih.gov/31559383/

Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood (2019)
https://pubmed.ncbi.nlm.nih.gov/31128893/

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis (2019)
https://pubmed.ncbi.nlm.nih.gov/31254223/

Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis (2019)
https://pubmed.ncbi.nlm.nih.gov/31663467/

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/30499246/

Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set (2018)
https://pubmed.ncbi.nlm.nih.gov/29637483/

Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set (2018)
https://pubmed.ncbi.nlm.nih.gov/29861786/

Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database (2018)
https://pubmed.ncbi.nlm.nih.gov/29148281/

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA (2018)
https://pubmed.ncbi.nlm.nih.gov/30324088/

Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database (2018)
https://pubmed.ncbi.nlm.nih.gov/29557701/

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial (2018)
https://pubmed.ncbi.nlm.nih.gov/30191421/

Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database (2018)
https://pubmed.ncbi.nlm.nih.gov/29952704/

PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol (2018)
https://pubmed.ncbi.nlm.nih.gov/29717036/

Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance (2018)
https://pubmed.ncbi.nlm.nih.gov/29142040/

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) (2018)
https://pubmed.ncbi.nlm.nih.gov/29343507/